                         SEQUENCE LISTING

<110>  Novartis AG
       Hesse, Matthew James
       Hornak, Viktor
       Joseph, Sajan
       Moser, Heinz Ernst
       Papillon, Julien
       Patel, Tajesh
       Robinson, Richard
       Tully, David Charles
       Yuan, Jun
 
<120>  COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRAL 
       RELATED DISEASES

<130>  PAT059097-WO-PCT

<160>  3     

<170>  PatentIn version 3.5

<210>  1
<211>  549
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  SARS-CoV-2 main protease

<400>  1

Met Ser Pro Ile Leu Gly Tyr Trp Lys Ile Lys Gly Leu Val Gln Pro 
1               5                   10                  15      


Thr Arg Leu Leu Leu Glu Tyr Leu Glu Glu Lys Tyr Glu Glu His Leu 
            20                  25                  30          


Tyr Glu Arg Asp Glu Gly Asp Lys Trp Arg Asn Lys Lys Phe Glu Leu 
        35                  40                  45              


Gly Leu Glu Phe Pro Asn Leu Pro Tyr Tyr Ile Asp Gly Asp Val Lys 
    50                  55                  60                  


Leu Thr Gln Ser Met Ala Ile Ile Arg Tyr Ile Ala Asp Lys His Asn 
65                  70                  75                  80  


Met Leu Gly Gly Cys Pro Lys Glu Arg Ala Glu Ile Ser Met Leu Glu 
                85                  90                  95      


Gly Ala Val Leu Asp Ile Arg Tyr Gly Val Ser Arg Ile Ala Tyr Ser 
            100                 105                 110         


Lys Asp Phe Glu Thr Leu Lys Val Asp Phe Leu Ser Lys Leu Pro Glu 
        115                 120                 125             


Met Leu Lys Met Phe Glu Asp Arg Leu Cys His Lys Thr Tyr Leu Asn 
    130                 135                 140                 


Gly Asp His Val Thr His Pro Asp Phe Met Leu Tyr Asp Ala Leu Asp 
145                 150                 155                 160 


Val Val Leu Tyr Met Asp Pro Met Cys Leu Asp Ala Phe Pro Lys Leu 
                165                 170                 175     


Val Cys Phe Lys Lys Arg Ile Glu Ala Ile Pro Gln Ile Asp Lys Tyr 
            180                 185                 190         


Leu Lys Ser Ser Lys Tyr Ile Ala Trp Pro Leu Gln Gly Trp Gln Ala 
        195                 200                 205             


Thr Phe Gly Gly Gly Asp His Pro Pro Lys Ser Asp Leu Glu Val Leu 
    210                 215                 220                 


Phe Gln Gly Pro Leu Gly Ser Ala Val Leu Gln Ser Gly Phe Arg Lys 
225                 230                 235                 240 


Met Ala Phe Pro Ser Gly Lys Val Glu Gly Cys Met Val Gln Val Thr 
                245                 250                 255     


Cys Gly Thr Thr Thr Leu Asn Gly Leu Trp Leu Asp Asp Val Val Tyr 
            260                 265                 270         


Cys Pro Arg His Val Ile Cys Thr Ser Glu Asp Met Leu Asn Pro Asn 
        275                 280                 285             


Tyr Glu Asp Leu Leu Ile Arg Lys Ser Asn His Asn Phe Leu Val Gln 
    290                 295                 300                 


Ala Gly Asn Val Gln Leu Arg Val Ile Gly His Ser Met Gln Asn Cys 
305                 310                 315                 320 


Val Leu Lys Leu Lys Val Asp Thr Ala Asn Pro Lys Thr Pro Lys Tyr 
                325                 330                 335     


Lys Phe Val Arg Ile Gln Pro Gly Gln Thr Phe Ser Val Leu Ala Cys 
            340                 345                 350         


Tyr Asn Gly Ser Pro Ser Gly Val Tyr Gln Cys Ala Met Arg Pro Asn 
        355                 360                 365             


Phe Thr Ile Lys Gly Ser Phe Leu Asn Gly Ser Cys Gly Ser Val Gly 
    370                 375                 380                 


Phe Asn Ile Asp Tyr Asp Cys Val Ser Phe Cys Tyr Met His His Met 
385                 390                 395                 400 


Glu Leu Pro Thr Gly Val His Ala Gly Thr Asp Leu Glu Gly Asn Phe 
                405                 410                 415     


Tyr Gly Pro Phe Val Asp Arg Gln Thr Ala Gln Ala Ala Gly Thr Asp 
            420                 425                 430         


Thr Thr Ile Thr Val Asn Val Leu Ala Trp Leu Tyr Ala Ala Val Ile 
        435                 440                 445             


Asn Gly Asp Arg Trp Phe Leu Asn Arg Phe Thr Thr Thr Leu Asn Asp 
    450                 455                 460                 


Phe Asn Leu Val Ala Met Lys Tyr Asn Tyr Glu Pro Leu Thr Gln Asp 
465                 470                 475                 480 


His Val Asp Ile Leu Gly Pro Leu Ser Ala Gln Thr Gly Ile Ala Val 
                485                 490                 495     


Leu Asp Met Cys Ala Ser Leu Lys Glu Leu Leu Gln Asn Gly Met Asn 
            500                 505                 510         


Gly Arg Thr Ile Leu Gly Ser Ala Leu Leu Glu Asp Glu Phe Thr Pro 
        515                 520                 525             


Phe Asp Val Val Arg Gln Cys Ser Gly Val Thr Phe Gln Gly Pro His 
    530                 535                 540                 


His His His His His 
545                 


<210>  2
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Substrate sequence of SARS-CoV-2 main protease

<400>  2

Ala Val Leu Ser Gly Phe Arg Lys Lys 
1               5                   


<210>  3
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Substrate sequence of SARS-CoV-2 main protease

<400>  3

Ala Val Leu Gln Ser Gly Phe Arg Lys Lys 
1               5                   10  


